

# Global Cell Therapy Market Outlook, Patent & Clinical Trials Insight 2028

<https://marketpublishers.com/r/G2A21FD2CB86EN.html>

Date: August 2021

Pages: 1800

Price: US\$ 3,000.00 (Single User License)

ID: G2A21FD2CB86EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global Cell Therapy Market Outlook, Patent & Clinical Trials Insight 2028' Report Highlights:

Global Cell Therapy Market Opportunity: > USD 45 Billion By 2028

Cell Therapy Clinical Trial Insight by Indication, Company and Country

Insight On More than 1600 Cell Therapies in Clinical Trials

Clinical & Commercial Insight On 32 Cell Therapies Available in Market

Dosage & Pricing Insight By Country & Region

COVID-19 Impact Analysis on Global market & Clinical Trials

Price & Product Insight By Region/Country

In last few years, cellular therapies have gained a considerable momentum in the management of wide range of diseases including cancer, hematological malignancies, autoimmune disorders, and damaged tissue. The cellular therapies mainly consists of hematopoietic stem cell transformation (HSCT), adoptive immune therapy for cancer, gene therapy for management of inherited deficiencies and bone marrow stromal cell (BMSC) therapy for the treatment of ischemic heart diseases. Researchers are currently

making huge investments in the development of such effective and safe treatment as an alternative to conventional therapies.

Currently, cell therapy is one of the most exciting fields in translational medicine as it can effectively alleviate the underlying cause of genetic and acquired disease. The cell therapy works by restoring or altering cells and it functions by cultivating or manipulating cells outside the body before they are again injected into patient's body. The cell therapies consist of all aspects of cellular immunotherapies, cellular medications, and other therapies which include cells from donor and recipients for cell therapies. Continuous research and development in cell therapy has accelerated at a fast rate, with the increasing number of products entering clinical trials and development.

The entrance of chimeric antigen T-cell therapy for the management of cancer has also driven the growth of market. Currently, two CAR T-cell products have been approved for the management of cancer which has shown high adoption rates in the market. Apart from T-cells, researchers are also utilizing NK cells as alternative vehicles for their CAR engineering, given their unique biological features and established safety profile in the allogeneic setting. In addition to this, other immune effector cells including gamma-delta T cells or macrophages are attracting interest and may be added to the repertoire of engineered cell therapies against cancer.

The global cell therapy market was valued at less than US\$ 20 Billion in 2020 and is expected to surpass US\$ 45 Billion by 2028. The market is mainly driven by the large number of clinical studies of cell based therapies which can be attributed to the presence of government and private funding agencies that are constantly offering grants to support projects across various stages of clinical trials. Furthermore, the need of better and targeted therapies in the management of diseases such as cancer and cardiovascular diseases has also resulted in overall increase in research and development activities, thus boosting the growth of market.

North America is expected to hold the largest share in the market during the forecast period. The large share of the region is mainly due to the presence of substantial number of pharmaceutical companies and research centers. The major key players in cell therapy market are Fibrocell Science, JCR Pharmaceuticals, Pharmicell, Osiris Therapeutics, Medipost, Vericel Corporation, Anterogen, Kolon TissueGene, Stemedica Cell Technologies, and AlloCure. In addition to this, Asia Pacific is expected to witness high CAGR rates due to rising investment by developers and consumers in educating themselves for advanced targeted therapies. Furthermore, the rise in healthcare expenditure and developing guidelines are expected to propel the growth of market in

this region.

## Contents

### **1. WHAT IS CELL THERAPY?**

- 1.1 Introduction
- 1.2 History & Evolution of Cell Therapy
- 1.3 Cell Therapy Classification

### **2. MECHANISM OF THERAPEUTIC ACTION IN CELL THERAPY**

### **3. EMERGENCE OF PERSONALIZED CELL THERAPY**

- 3.1 Overview of Personalized Cell Therapy
- 3.2 Personalized Cell Therapy Using Epigenetic Tools
- 3.3 Personalized Cell Therapy through Mesenchymal Stem Cells
- 3.4 Treatment of Parkinson's Disease through iPSCs
- 3.5 Case Study: Personalized Cell Therapy for Pulpitis Using Autologous Dental Pulp Stem Cells & Leukocyte Platelet Rich Fibrin

### **4. CELL THERAPY APPLICATION BY THERAPEUTIC AREAS**

- 4.1 Cardiovascular Disease
- 4.2 Neurological Disorders
- 4.3 Inflammatory Diseases
- 4.4 Diabetes

### **5. ROLE OF CELL THERAPY IN CANCER THERAPEUTICS**

### **6. GLOBAL CELL THERAPY CLINICAL TRIALS 2021 -2028**

- 6.1 By Phase
- 6.2 By Country/Region
- 6.3 By Company
- 6.4 By Indication
- 6.5 By Patient Segment
- 6.6 By Route Of Administration

### **7. IMPACT OF COVID-19 ON CELL THERAPY RESEARCH LANDSCAPE**

## **8. GLOBAL CELL THERAPIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 8.1 Unknown
- 8.2 Research
- 8.3 Preclinical
- 8.4 Clinical
- 8.5 Phase-0
- 8.6 Phase-I
- 8.7 Phase-I/II
- 8.8 Phase-II
- 8.9 Phase-II/III
- 8.10 Phase-III
- 8.11 Preregistration
- 8.12 Registered

## **9. GLOBAL CELL THERAPY MARKET OUTLOOK**

- 9.1 Current Market Scenario
- 9.2 Cell Therapy Market by Cell Source

## **10. US - CELL THERAPY DOSAGE & COST ANALYSIS**

- 10.1 Allocord
- 10.2 Laviv
- 10.3 Maci
- 10.4 Clevecord
- 10.5 Hemacord
- 10.6 Ducord
- 10.7 Provenge
- 10.8 HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood Bank)
- 10.9 HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)
- 10.10 HPC, Cord Blood (Bloodworks)
- 10.11 HPC, Cord Blood (MD Anderson Cord Blood Bank)
- 10.12 Gintuit
- 10.13 Kymriah\*
- 10.14 Yescarta\*
- 10.15 Carticel
- 10.16 Abecma (Idecabtagene Vicleucel)

10.17 Breyanzi (Lisocabtagene Maraleucel)

## **11. SOUTH KOREA - CELL THERAPY DOSAGE & COST ANALYSIS**

11.1 Cartistem

11.2 Chondron

11.3 KeraHeal

11.4 Cellgram

11.5 Cure Skin Injection

## **12. EUROPE - CELL THERAPY DOSAGE & COST ANALYSIS**

12.1 Holoclar (Europe)

12.2 Yescarta (EU)

12.3 Kymriah (EU)

12.4 Alofisel (EU)

12.5 Strimvelis (EU)

12.6 Urocell (Germany/Switzerland/Belgium)

12.7 CellSpray (Belgium)

## **13. JAPAN - CELL THERAPY DOSAGE & COST ANALYSIS**

13.1 Temcell HS (Japan)

13.2 HeartSheet (Japan)

13.3 Stemirac

## **14. SOUTH KOREA - CELL THERAPY DOSAGE & COST ANALYSIS**

14.1 Neuronata-R lenzumestrocel (South Korea)

14.2 Invossa-K (South Korea)

14.3 Adipocell / Cupistem/ Queencell (Korea)

## **15. REST OF WORLD - CELL THERAPY DOSAGE & COST ANALYSIS**

15.1 Chondrocytes-T-Ortho-ACI (Australia)

15.2 Prochymal (Canada/New Zealand)

15.3 Apceden (India)

15.4 BioCartil (Israel)

15.5 Nucel

## 15.6 CureXcell (Israel)

## 16. GLOBAL CELL THERAPY MARKET SCENARIO

### 16.1 US

### 16.2 South Korea

### 16.3 Europe

### 16.4 Japan

### 16.5 China

### 16.6 Rest of the World

## 17. CELL THERAPY RESEARCH INSIGHTS AT UNIVERSITY LEVEL

### 17.1 Novel Autologous CAR-T Cell Therapy in Multiple Myeloma

### 17.2 Encouraging Cell Therapy Results with Cocoon Automated Platforms

### 17.3 CNCT19 Received Breakthrough Designation in China

### 17.4 Positive Results of MultiStem for ARDS in One-Bridge Study

### 17.5 MB-102 Initiated Phase-I/II Clinical Trial

### 17.6 G-NK Cells in Combination with Monoclonal Antibodies for Multiple Myeloma

### 17.7 Phase-III Trial Results of Omidubicel in Various Cancers

### 17.8 Novel Cell Therapy Combination shows Potential in NSCLC

## 18. STRATEGIC ALLIANCES FOR PROMOTING CELL THERAPY RESEARCH

### 18.1 Kite Pharma & Appia Bio New Collaboration for Allogeneic Cell Therapy

### 18.2 New Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs

### 18.3 Lilly & Sigilon Therapeutics to Develop Cell Therapies for Diabetes

### 18.4 Artiva Biotherapeutics Expand its Facilities in San Diego

### 18.5 Orion & Blood Service Launch Collaboration for Cancer Cell Therapy

### 18.6 Bayer & Atara Biotherapeutics Alliance for Cell Therapies in Solid Tumors

### 18.7 Tata Memorial Hospital & IIT Partnership for First CAR-T Cell Therapy in India

### 18.8 Mustang Bio Partnership with Mayo Clinic on Novel Cell Therapy

### 18.9 Cellares Partner with Poseida Therapeutics to Advance Cell Therapy Manufacturing

### 18.10 Joint Venture by Orgenesis & Cure Therapeutics for Cell & Gene Therapies

## 19. TREG CELLS – THE NEXT STEP TO ADVANCE CELL THERAPY

### 19.1 Introduction to Treg Cell

19.2 Isolation & Expansion of Treg Cell

19.3 Mechanism of Action

19.4 Clinical Trials of Treg Cell Therapy

19.5 Treg Cell Therapy for the Treatment of Autoinflammatory & Autoimmune Diseases

19.6 Future Prospects of Treg Cell Therapy

## **20. GLOBAL CELL THERAPY MARKET FUTURE PROSPECTS**

### **21. MARKETED CELL THERAPIES CLINICAL INSIGHT BY COMPANY & INDICATION**

21.1 Abecma

21.2 Yescarta

21.3 Breyanzi

21.4 NEURONATA-R

21.5 Provenge

21.6 RYONCIL / Prochymal

21.7 Kymriah

21.8 Chondrotransplant DISC

21.9 MACI

21.10 Carticel

21.11 STEMIRAC

21.12 HeartSheet

21.13 Strimvelis

21.14 Cartistem

21.15 Adipocell (Anterogen)

21.16 Alofisel

21.17 Zalmoxis

21.18 Cellgram

21.19 INVOSSA-K inj

21.20 APCEDEN for RCC

21.21 Laviv

21.22 BioCart

21.23 Gintuit

21.24 Holoclar

21.25 MyoCell

21.26 CellSpray

21.27 CureXcell

21.28 CHONDRON

21.29 NuCel

21.30 Dendritic Cell-Activated Cytokine-Induced killer Cells - Shanghai Jia Fu Medical

21.31 Urocell

21.32 Autologous chondrocyte implant – TETEC

## **22. COMPETITIVE LANDSCAPE**

22.1 Athersys Inc.

22.2 Baxter Healthcare Corporation

22.3 Bone Therapeutics

22.4 Celgene Corporation

22.5 Cell Medica

22.6 Cellerant Therapeutics

22.7 FibrocellScience

22.8 Genzyme Corporation

22.9 Green Cross Cell

22.10 Histogenics Corporation

22.11 Intrexon Corporation

22.12 Intercytex

22.13 ISTO Biologics

22.14 MacroCure

22.15 Mesoblast

22.16 Molmed

22.17 Nuo Therapeutics Inc

22.18 OmniCytex

22.19 Opexa Therapeutics

22.20 Organogenesis

22.21 Pharmicell

22.22 TCA Cellular Therapy

22.23 Stem Cell Inc.

22.24 Teva Pharmaceuticals

22.25 Tigenix

22.26 Vericel Corporation

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Cell Therapy Pathway
- Figure 1-2: Evolution of Cell Therapy
- Figure 1-3: Types of Cell Therapy
- Figure 1-4: Steps in Allogeneic Cell Therapy
- Figure 1-5: Steps in Autologous Cell Therapy
- Figure 1-6: Steps in the Derivation of Human Embryonic Stem Cells
- Figure 1-7: Cardinal Neural Stem Cell Properties
- Figure 1-8: Mesenchymal Stem Cells Therapy Process
- Figure 2-1: Cell Therapy Mechanism
- Figure 3-1: Advantages of Personalized Cell Therapy
- Figure 3-2: Mesenchymal Stem Cells (MSCs) in Autism Spectrum Disorder (ASD) Treatment
- Figure 3-3: Steps of iPSC Transplantation
- Figure 4-1: Global - Mortality Caused by Non Communicable Disease (%)
- Figure 4-2: Cell Therapy for Cardiovascular Disease
- Figure 4-3: Overview of Stem Cell Therapy in Cardiovascular Disease
- Figure 4-4: Cell Therapy in Neurological Disorders
- Figure 4-5: Cell Therapy in Treatment of Alzheimer's disease
- Figure 4-6: Cell Therapy in Diabetes
- Figure 6-1: Global - Cell Therapies Clinical Pipeline by Phase (%), 2021 till 2028
- Figure 6-2: Global - Cell Therapies Clinical Pipeline by Phase (Number), 2021 till 2028
- Figure 6-3: Global - Cell Therapies Clinical Pipeline by Region (Number), 2021 till 2028
- Figure 6-4: Global - Cell Therapies Clinical Pipeline by Company (Number), 2021 till 2028
- Figure 6-5: Global - Cell Therapies Clinical Pipeline by Indication (Number), 2021 till 2028
- Figure 6-6: Global - Cell Therapies Clinical Pipeline by Patient Segment (Number), 2021 till 2028
- Figure 6-7: Global - Cell Therapies Clinical Pipeline by Route Of Administration (Number), 2021 till 2028
- Figure 9-1: Cell Therapy- The Final Therapeutic Pillar of Healthcare
- Figure 9-2: Global - Cell Therapy Market (US\$ Billion), 2020 - 2028
- Figure 9-3: Process for Conventional Drug Delivery
- Figure 9-4: Process for Induced Pluripotent Stem Cell Based Drug Delivery
- Figure 9-5: Global- Induced Pluripotent Stem Cell Therapy Market (US\$ Billion), 2020 -

2028

Figure 9-6: Steps involved in Bone Marrow Transplant

Figure 10-1: US – Allocord Infusion per Hour (Milliliters), Adult & Children

Figure 10-2: Allocord – Composition of Single Unit of Suspension for Injection (Million Cells)

Figure 10-3: Laviv – FDA Approval & Patent Expiration Year

Figure 10-4: Laviv – Cost of Single Treatment Cycle & Full Treatment Cost (US\$), August'2021

Figure 10-5: MACI – Mixed Cell Populations for Tissue Repair & Separation Technique Related Patent Issue & Expiration Year

Figure 10-6: MACI – Administration Related Patent Issue & Expiration Year

Figure 10-7: MACI – Method of Manufacturing Related Patent Issue & Expiration Year

Figure 10-8: MACI – Minimum & Maximum Cost of Single Sheet of 500,9000 Cells/cm<sup>2</sup> (US\$), August'2021

Figure 10-9: MACI – Cost for Treatment of Fractures & Cartilage Injury (US\$), May'2020

Figure 10-10: MACI – Cost for Treatment of Fractures & Cartilage Injury (US\$), May'2020

Figure 10-11: US – Clevecord Dosage of Nucleated Cells per Kilogram (Million) & Average Cost (US\$)

Figure 10-12: Hemacord – Composition of Single Unit of Suspension for Injection (Million Cells)

Figure 10-13: Ducord – Composition of Single Unit of Suspension for Injection (Million Cells)

Figure 10-14: Provenge – Patent Issue & Expiration Year

Figure 10-15: Provenge – Price of 250ml Supply & Price per ml (US\$), August'2021

Figure 10-16: Provenge – Price of Single Treatment Cycle & Price for Full Treatment (US\$), August'2021

Figure 10-17: HPC Cord Blood (Clinimmune Labs) – Composition of Single Unit of Suspension for Injection (Million Cells)

Figure 10-18: Kymriah – FDA Approval Year by Indication

Figure 10-19: Kymriah – Number of Patents by Region

Figure 10-20: Kymriah – Number of US Patents by Nature of Patent

Figure 10-21: US – Kymriah Average Dosage of CAR positive viable T cells (Paediatric & Adults), August 2017

Figure 10-22: Kymriah – Cost of Intravenous Suspension & Additional Expenditure (US\$), August'2021

Figure 10-23: Kymriah – Minimum & Maximum Dose for Patients with Less than 50Kg Weight for ALL Management (Million Cells/ Kg), May'2020

Figure 10-24: Kymriah – Minimum & Maximum Dose for Management of Large B-Cell Lymphoma (Million Cells/ Kg), May'2020

Figure 10-25: Kymriah - Annual Sales Value (US\$ Million), 2017 - 2019

Figure 10-26: Global - Kymriah Quarterly Sales Value (US\$ Million), 2019

Figure 10-27: Global - Kymriah Quarterly Sales Value (US\$ Million), 2020

Figure 10-28: Global - Kymriah Half Yearly Sales Value (US\$ Million), Q1 & Q2, 2020

Figure 10-29: Yescarta – FDA Approval & US Patent Expiration Year

Figure 10-30: US – Yescarta Target Dose vs Maximum Dose of CAR-positive viable T cells, October 2017

Figure 10-31: Yescarta – Cost of Intravenous Suspension & Additional Expenditure (US\$), August'2021

Figure 10-32: Yescarta – Dose for Average Human & Maximum Dose (Million Cells), August'2021

Figure 10-33: Yescarta - Annual Sales Value (US\$ Million), 2017 - 2020

Figure 10-34: Yescarta - Annual Sales Value by Region (US\$ Million), 2019

Figure 10-35: Yescarta – Annual Sales Value by Region (%), 2019

Figure 10-36: Yescarta - Annual Sales Value by Region (US\$ Million), 2020

Figure 10-37: Yescarta - Annual Sales Value by Region (US\$ Million), 2020

Figure 10-38: Global - Yescarta Quarterly Sales Value (US\$ Million), 2018 & 2019

Figure 10-39: Global - Yescarta Quarterly Sales Value (US\$ Million), 2020

Figure 10-40: US - Yescarta Quarterly Sales Value (US\$ Million), 2020

Figure 10-41: Europe - Yescarta Quarterly Sales Value (US\$ Million), 2020

Figure 10-42: Global - Yescarta Half Yearly Sales Value (US\$ Million), Q1 & Q2, 2021

Figure 10-43: US - Yescarta Half Yearly Sales Value (US\$ Million), Q1 & Q2, 2021

Figure 10-44: Europe - Yescarta Half Yearly Sales Value (US\$ Million), Q1 & Q2, 2021

Figure 10-45: Carticel - FDA Approval & Patent Expiration Year

Figure 10-46: Carticel – Minimum & Maximum Cost of Single Vial of 12 Million Cells/0.4ml (US\$), August'2021

Figure 10-47: US – Carticel Minimum & Maximum Cost (US\$), 2018

Figure 10-48: Abecma – Minimum & Maximum Dosage of CAR positive viable T Cells (Million Cells), August'2021

Figure 10-49: Breyanzi – Minimum & Maximum Dosage of CAR positive viable T Cells (Million Cells), August'2021

Figure 11-1: Cartistem – Average Cost of Regenerative & Additional Treatment (US\$), August'2021

Figure 11-2: Cartistem – Annual Sales Value (KRW/US\$ Million), 2012, 2019 & 2020

Figure 11-3: Chondron – Average Cost of Knee Cartilage Defect Treatment (KRW/US\$), May'2020

Figure 11-4: South Korea - KeraHeal vs KeraHeal-Allo Dosage form (Millilitres Cell

Suspension)

Figure 11-5: Cellgram – Average Cost of Intravenous Suspension (KRW/US\$), May'2020

Figure 12-1: Holoclar – Cost of Single & Both Eyes Treatment (GBP/US\$), May'2020

Figure 12-2: Holoclar – Recommended Minimum & Maximum Dose (Cells/cm<sup>2</sup> of Cornea Surface), May'2020

Figure 12-3: Yescarta – FDA Approval, EU Approval & US Patent Expiration Year

Figure 12-4: Yescarta – Cost of Intravenous Suspension & Additional Expenditure (EUR/US\$), August'2021

Figure 12-5: Yescarta – Dose for Average Human & Maximum Dose (Million Cells)

Figure 12-6: Yescarta - Annual Sales Value (US\$ Million), 2017 - 2020

Figure 12-7: Yescarta - Annual Sales Value by Region (US\$ Million), 2019

Figure 12-8: Yescarta – Annual Sales Value by Region (%), 2019

Figure 12-9: Yescarta - Annual Sales Value by Region (US\$ Million), 2020

Figure 12-10: Yescarta - Annual Sales Value by Region (US\$ Million), 2020

Figure 12-11: Global - Yescarta Quarterly Sales Value (US\$ Million), 2018 & 2019

Figure 12-12: Global - Yescarta Quarterly Sales Value (US\$ Million), 2020

Figure 12-13: US - Yescarta Quarterly Sales Value (US\$ Million), 2020

Figure 12-14: Europe - Yescarta Quarterly Sales Value (US\$ Million), 2020

Figure 12-15: Global - Yescarta Half Yearly Sales Value (US\$ Million), Q1 & Q2, 2021

Figure 12-16: US - Yescarta Half Yearly Sales Value (US\$ Million), Q1 & Q2, 2021

Figure 12-17: Europe - Yescarta Half Yearly Sales Value (US\$ Million), Q1 & Q2, 2021

Figure 12-18: Kymriah – FDA Approval Year by Region

Figure 12-19: Kymriah – Number of Patents by Region

Figure 12-20: Kymriah – Cost of Intravenous Suspension & Additional Expenditure (GBP/US\$), August'2021

Figure 12-21: Kymriah – Minimum & Maximum Dose for Patients with Less than 50Kg Weight for ALL Management (Million Cells/ Kg), August'2021

Figure 12-22: Kymriah – Minimum & Maximum Dose for Management of Large B-Cell Lymphoma (Million Cells/ Kg), August'2021

Figure 12-23: Alofisel – Price For 4 Vials Supply & Price for Single Vial (US\$), August'2021

Figure 13-1: Japan - Temcell Dosage of Cells per Killogram Body Weight (Million)

Figure 13-2: Cost for Single Bag, Single Treatment Cycle & Full Treatment (JPY/US\$), May'2020

Figure 13-3: HeartSheet A Kit – Cost of Single Kit (JPY/US\$), August'2021

Figure 13-4: HeartSheet B Kit – Cost of Single Kit (JPY/US\$), August'2021

Figure 13-5: Stemaric – Minimum & Maximum Dose (Million Cells)

Figure 14-1: Neuronata R – Annual Treatment Cost (KRW/US\$), August'2021

Figure 14-2: Invossa – Minimum & Maximum Cost of Suspension (KRW/US\$), August'2021

Figure 14-3: Cupistem – Minimum & Maximum Cost of Suspension (US\$), August'2021

Figure 15-1: Australia - Ortho-ACI Constituents of Dulbecco's Modified Eagle Medium (DMEM) nutrient mixture

Figure 15-2: Australia - Ortho-ACI Average Dose (Million Cells) & Cost of Treatment (US\$)

Figure 15-3: Apceden – Median Progression-Free Survival in Patients with Solid Tumors (Number of Months)

Figure 15-4: Apceden – Median Progression Free Survival in Patients with Progressive Solid Tumors (Number of Months)

Figure 15-5: Apceden – Availability of Vial & Vials Required in Apceden Therapy

Figure 15-6: Apceden – Intervals Between Multiple Doses of Treatment

Figure 15-7: Apceden – Cost of Single Vaccine, 6 Vaccines & 12 Vaccines (US\$/INR), August'2021

Figure 16-1: Significance of Cell Therapy Market Technology

Figure 16-2: Drivers for Growth of Cell Therapy in Japan

Figure 16-3: Criteria Impacting Successful Cell Therapy

Figure 16-4: China Cell Therapy Market Strategy

Figure 16-5: Rest of the World – Cell Therapy Clinical Trial by Region (%), 2019

Figure 19-1: Working of CD4+ & CD25+ Regulatory T-Cell

Figure 19-2: Mechanism of Action of Treg Cell

Figure 19-3: Therapeutic Action of Treg Cell

Figure 19-4: Future Applications of Treg Cells

Figure 20-1: Growth Opportunities for Cell Therapy

Figure 22-1: Bone Therapeutics Clinical Pipeline

Figure 22-2: Celgene Clinical Pipeline

Figure 22-3: Cell Medica Therapeutics Clinical Pipeline

Figure 22-4: Cellerant Therapeutics Clinical Pipeline

Figure 22-5: Fibrocell Science Clinical Pipeline

Figure 22-6: Intrexon Clinical Pipeline

Figure 22-7: Mesoblast Clinical Pipeline

Figure 22-8: Molmed Clinical Pipeline

Figure 22-9: Tigenix Clinical Pipeline

Figure 22-10: Vericel Corporation Clinical Pipeline

## List Of Tables

### LIST OF TABLES

Table 1-1: Difference between Allogeneic & Autologous Cell Therapy

Table 19-1: Functions of Effector T-Cell & Treg Cell

## I would like to order

Product name: Global Cell Therapy Market Outlook, Patent & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/G2A21FD2CB86EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2A21FD2CB86EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970